Comparison · NCT05186818-sae
Aficamten up to 20 mg vs Placebo to Match Aficamten: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Aficamten up to 20 mg vs Placebo to Match Aficamten: serious adverse events. Trial comparisons, record NCT05186818-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05186818-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0563 | 0.0288 | 0.107 | wilson | |
| Risk in group 2 | 0.0929 | 0.0551 | 0.152 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0365 | -0.102 | 0.0269 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.607 | 0.26 | 1.42 | log | |
| Odds ratio, group 1 over group 2 | 0.583 | 0.234 | 1.45 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Aficamten up to 20 mg than on Placebo to Match Aficamten | 27.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Aficamten up to 20 mg | Participants received 5 mg, 10 mg, 15 mg, or 20 mg of aficamten; dose levels were guided by echocardiography assessments. Treatment was administered for up to 24 weeks.~Aficamten (5 mg, 10 mg, 15 mg, and 20 mg): Aficamten tablets were administered orally once daily. | 8 | 142 | EG000 |
| Group 2 | Placebo to Match Aficamten | Participants received placebo for up to 24 weeks.~Placebo to match aficamten: Placebo tablets were administered orally once daily. | 13 | 140 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 28 Weeks
Source ClinicalTrials.gov
Trial
- Title
- Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
- NCT number
- NCT05186818
- Phases
- PHASE3
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten
- Lead sponsor
- Cytokinetics
- Results first posted
- 2026-03-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05186818?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05186818-sae